PCM Trials closes second strategic acquisition of 2024

PCM Trials closes second strategic acquisition of 2024

The Denver Business Journal details our recent acquisition of EmVenio Research, and our second acquisition of 2024. The acquisition grants PCM Trials access to new, mobile community site networks in the United States and United Kingdom. The acquisition of EmVenio Research, along with PCM Trials of Clinical Trial Service in January, make PCM Trials the largest and most experienced local provider of clinical research access on a global scale.

Read the complete article here.